Fig. 4: artLCMV treatment induces Cxcl13-expressing FSCs in the TME.

Mice were inoculated with B16F10-mCherry and immunized i.t. on day 7 with artLCMV-TRP2 and tumors were analyzed on day 11. a Frequency of PDPN⁺ cells in tumors from mice treated i.t. with artLCMV-TRP2. b Quantitative real-time PCR for Ccl19 and Cxcl13 mRNA expression in PDPN⁺ FSCs sorted from tumors on day 11. c Confocal microscopy of tumors from Cxcl13-Cre/tdTom EYFP mice treated as indicated. Scale bars 700 μm (overview) and 80 μm (boxed areas). Arrowheads indicate EYFP⁺ PDPN⁺ FSCs. d Frequency of EYFP⁺ PDPN⁺ in Cxcl13-Cre/tdTom EYFP mice. e Frequency of tdTom⁺ cells among EYFP⁺ PDPN⁺ cells as marker for current CXCL13 expression. Dots represent individual mice and lines indicate mean values ± s.e.m values. Pooled data from two independent experiments with n = 7 (PBS) and n = 6 (artLCMV-TRP2) mice (a, d, e); n = 7 (Ccl19, PBS; Ccl19, artLCMV-TRP2; Cxcl13, artLCMV-TRP2) and n = 6 (Cxcl13, PBS) mice (b). Representative images from n = 4 (PBS) and n = 5 (artLCMV-TRP2) mice (c). Statistical analysis was performed using unpaired two-tailed Student’s t test (a, b, d, e) with *P < 0.05: **P < 0.01; ***P < 0.001. Source data and exact P values are provided in the Source data file.